Stock appreciation rights are compensation awards that pay the positive increase in company share value above a stated base price without requiring a share purchase.
Stock appreciation rights (SARs) are compensation awards that entitle a participant to the positive increase in value of a stated number of company shares above a fixed base price. Unlike a stock option, a SAR generally does not require the participant to pay the base price to receive the appreciation value.
The simplified gross value is:
SAR value = number of exercisable SARs x max(settlement share value - base price, 0)
The base price is a reference amount, not usually cash the participant must pay. This is the key economic difference from an employee stock option.
Assume an employee exercises 2,000 vested SARs with a base price of USD 30 when the measured share value is USD 42.
USD 42 - USD 30 = USD 122,000 x USD 12 = USD 24,000The gross cash payout is USD 24,000 before tax withholding, payroll deductions, and fees.
If the plan settles the USD 24,000 value in shares measured at USD 42:
USD 24,000 / USD 42 = 571.43 shares
The plan determines how fractional shares and withholding are handled, so the participant may receive fewer than 571 whole shares plus cash or another adjustment.
The participant does not pay 2,000 x USD 30 to receive the SAR value. If the share value is USD 28 instead, the SAR has zero intrinsic value under this formula and exercising would provide no gross payout.
| Type | Relationship to a stock option | Practical effect |
|---|---|---|
| Freestanding SAR | Independent award | Can be exercised or settled according to its own terms. |
| Tandem SAR | Granted with a related stock option | Exercising the SAR generally reduces or cancels the linked option, and exercising the option can cancel the SAR. |
Tandem awards let the holder capture appreciation without funding a full option exercise, but they do not provide two separate payouts over the same shares. The plan must explain the cancellation ratio, tax withholding, and treatment of a partial exercise.
| Award | Value received | Cash purchase required? | Ownership before settlement? |
|---|---|---|---|
| Stock appreciation right | Positive appreciation above base price | Usually no | No |
| Appreciation-only phantom stock | Positive increase in hypothetical share value | Usually no | No |
| Full-value phantom stock | Full reference value at settlement | Usually no | No |
| Stock option | Positive spread if shares are bought below market value | Yes, absent a cashless or net method | No |
| Restricted stock unit | Full value of shares or cash delivered at settlement | Usually no | No |
An appreciation-only phantom stock award can have a similar formula. A SAR, however, often has an express exercise window and base price analogous to an option. Actual terminology varies, so readers should compare legal rights rather than labels.
| Settlement method | Company impact | Participant impact |
|---|---|---|
| Cash | Requires cash and generally creates no new shares | Receives cash; no continuing share exposure after payment |
| Shares | Preserves cash but can create dilution | Receives shares and becomes exposed to later market movements |
| Net shares after withholding | Reduces shares delivered | Withholding and share price affect the net share count |
| Company or participant election | Can affect accounting classification | Choice exists only under the plan and may be constrained |
Cash settlement can create a large obligation when the share price rises, which is also when the SAR has the strongest incentive value. Share settlement can reduce that cash pressure but use the equity plan reserve and increase share dilution.
SARs are share-based payment transactions. Under IFRS 2, a cash-settled SAR liability is measured at fair value and remeasured at each reporting date until settlement, with changes affecting compensation expense. The calculation generally requires more than current intrinsic value because expected volatility, remaining life, dividends, interest rates, vesting, and exercise behavior can affect fair value.
Equity-settled SARs can follow different accounting mechanics. Classification depends on the contractual settlement terms and applicable reporting framework, not merely on whether the award is called a SAR.
Investors should distinguish:
For a typical U.S. participant, value delivered on exercise or settlement is generally compensation income subject to the applicable reporting and withholding rules. The exact timing can differ for employees, nonemployees, deferred settlement, and cross-border service.
Under U.S. Section 409A regulations, a SAR over qualifying service-recipient stock can generally remain outside Section 409A when its base price is at least fair market value at grant and it has no additional deferral feature. A discounted SAR, an impermissible payment delay, or some modifications and extensions can change that result.
Private companies therefore need defensible fair market value at grant and consistent award administration. Section 409A is technical and penalties can fall on the participant, so plan-specific professional review is appropriate.
This article is educational. It does not provide tax, legal, accounting, employment, compensation, or investment advice. Award outcomes depend on the governing documents, jurisdiction, and settlement facts.